Drugs facing the most patent expirations this year

Expiring drug patents are continuously driving innovation, as branded firms seek out new high-margin opportunities.

Examining the patent expirations by year can indicate which pharmaceutical companies face the most peril from loss of patent protection.

This chart shows which pharmaceutical companies face the most patent expirations this year.

The drug companies facing the most patent expirations this year are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Accurate Forecasting of Product Returns Essential to Pharmaceutical Financial Fitness

Accurate Forecasting of Product Returns Essential to Pharmaceutical Financial FitnessIn pharmaceuticals, drug patents and exclusivity are similar, but not identical. Drug patents are intellectual property rights conferred by the US Patent and Trademark Office, and they can be granted at any time during drug development. Exclusivity has to do with delays and prohibitions on competitor drugs that are granted upon approval of a drug. The holder of the New Drug Approval (NDA) becomes eligible for exclusivity by meeting certain requirements.

The period of exclusivity and the terms of the drug patent may run concurrently, or they may not. The reason for exclusivity is to balance new drug innovation with greater drug access in the form of generics. When exclusivity ends, the handling of returns to the manufacturer can have a significant effect on revenues…
See more …

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Cream dosed drug patent expirations by year

This chart shows the patent expirations for cream dosed drugs over the next decade.

The term of drug patents varies. The basic term for a patent is 20 years from the date of patent filing, which generally occurs several years before a drug is approved.
This means that drugs may have 6-12 years of patent-protected sales after launch. There are conditions under which drug patents can be extended, for example to
compensate for time spent waiting for Food and Drug Agency (FDA) review, or for responding to an FDA request for pediatric testing.

Drug patent expirations can also be used as a bellwether for the pharmaceutical industry — a
rise, or fall, in the number of anticipated patent expirations can predict outcomes for branded pharmceutical companies,
generic producers, and for healthcare payers.

The long-range forecast presented here can help model pharmaceutical industry trends for cream dosed drugs over the coming decade.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

A drug by any other name would work just as well — making sense of drug names

A drug by any other name would work just as well — making sense of drug namesIn William Shakespeare’s play Romeo and Juliet, Juliet uses the phrase “A rose by any other name would smell just as sweet” to argue that it does not matter that
Romeo is from her family rival’s house of Montague. Likewise, drug naming is used to indicate that drugs from different companies have common ingredients and efficacy…
See more …

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most drug patents in Cyprus?

This chart shows the pharmaceutical companies with the most patents in Cyprus.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

For a global perspective, see the Drug companies with the greatest global patent coverage.

The companies with the greatest patent coverage in Cyprus are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Mannkind drug AFREZZA

Annual Drug Patent Expirations for AFREZZA
Annual Drug Patent Expirations for AFREZZA

Afrezza is a drug marketed by Mannkind
and is included in one NDA. It is available from two suppliers. There are thirty-one patents protecting this drug.

This drug has three hundred and fifty-eight patent family members in twenty-five countries.

The generic ingredient in AFREZZA is insulin recombinant human. Two suppliers are listed for this compound. Additional details are available on the insulin recombinant human profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Jazz Pharms drug XYREM

Annual Drug Patent Expirations for XYREM
Annual Drug Patent Expirations for XYREM

Xyrem is a drug marketed by Jazz Pharms
and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in XYREM is sodium oxybate. One supplier is listed for this compound. Additional details are available on the sodium oxybate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Novartis drug SANDOSTATIN LAR

Annual Drug Patent Expirations for SANDOSTATIN+LAR
Annual Drug Patent Expirations for SANDOSTATIN+LAR

Sandostatin Lar is a drug marketed by Novartis
and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

The generic ingredient in SANDOSTATIN LAR is octreotide acetate. One supplier is listed for this compound. Additional details are available on the octreotide acetate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most drug patents in Finland?

This chart shows the pharmaceutical companies with the most patents in Finland.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

For a global perspective, see the Drug companies with the greatest global patent coverage.

The companies with the greatest patent coverage in Finland are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com